The commentary “A Promising Leap in Treating Large Granular Lymphocytic Leukemia: Reflections on a Multicenter Phase II Study of Thalidomide-Based Therapy” by Xue Kong and Ken H. Young from Duke University, published in Blood Science (2025, Vol. 7, e00239), reviews a recent multicenter Phase II clinical trial showing remarkable efficacy of a thalidomide–prednisone–methotrexate (TPM) regimen in large granular lymphocytic leukemia (LGLL). The findings point to a significant potential shift in managing this rare and challenging hematologic malignancy.Background
Large granular lymphocytic leukemia (LGLL) is an uncommon clonal lymphoproliferative disorder marked by the expansion of cytotoxic CD8⁺ T cells (T-LGLL) or NK cells (NK-LGLL), accounting for 2–6% of chronic lymphoproliferative diseases. It is more prevalent in Asian populations and frequently presents with neutropenia, anemia, recurrent infections, and autoimmune conditions such as rheumatoid arthritis and Sjögren’s syndrome.
Although often indolent, LGLL causes significant chronic morbidity. Aberrant activation of the JAK/STAT pathway drives clonal expansion and cytokine overproduction, forming the molecular basis for current immunosuppressive therapies including methotrexate, cyclophosphamide, and cyclosporine. However, complete remissions occur in only about half of patients and relapses are common, making new treatment approaches urgently needed.
The Phase II TPM Study
To address these unmet needs, investigators conducted a multicenter Phase II trial evaluating a thalidomide-based triplet regimen: thalidomide (100 mg daily for up to 2 years), prednisone (alternate-day taper), and methotrexate (weekly dosing). The study, conducted from 2020 to 2022, enrolled 52 symptomatic LGLL patients—both newly diagnosed and previously treated—capturing a broad spectrum of clinical presentations, including severe anemia, transfusion dependence, and autoimmune complications.
Results were striking. Complete remission (CR) was achieved in 75% of patients, and the overall response rate (ORR) exceeded 90%, markedly surpassing historical benchmarks for LGLL. Median progression-free survival reached 40 months. Hematologic recovery was rapid, with most patients improving within 3 months and achieving CR by 6 months. Importantly, patients with severe cytopenias or STAT3 mutations—typically associated with poor prognosis—also responded robustly, highlighting the regimen’s broad clinical activity.
（Blood Science. 7(3):e00239, September 2025.）
Mechanistic Insights
Correlative analyses provided insight into the TPM regimen’s biological effects. Before therapy, patients exhibited elevated pro-inflammatory cytokines such as IL-6, IL-8, and CCL3, consistent with LGLL’s immune-driven pathology. These cytokines declined markedly after treatment, indicating restoration of immune homeostasis.
Mechanistically, the regimen works through complementary pathways: • Thalidomide reduces TNF-α and inflammatory cytokines while stabilizing immune regulation. • Methotrexate suppresses JAK/STAT signaling, inhibiting clonal lymphocyte proliferation. • Prednisone provides rapid cytoreduction and symptom relief during induction, with tapering to minimize long-term toxicity.
Together, these effects target both inflammatory signaling and malignant clone expansion, aligning with LGLL’s underlying biology.
Safety and Limitations
The TPM regimen was overall well-tolerated. Peripheral neuropathy—seen in about 25% of patients—was typically mild and manageable. Serious adverse events were rare, and no unexpected toxicities arose despite prolonged thalidomide exposure.
However, some limitations warrant caution. The absence of a control arm prevents direct comparison with existing frontline treatments. The study cohort was relatively young (median age 54), which may limit generalizability. Although follow-up of nearly 30 months provided valuable early outcomes, data on long-term relapse and late toxicity are still needed.
Conclusion and Future Directions
The Phase II TPM trial represents one of the most promising advances in LGLL therapy in decades. By combining targeted immunomodulation with suppression of aberrant signaling, the regimen achieved unprecedented remission rates with favorable tolerability. Future randomized Phase III trials will be essential to validate these results, determine optimal duration, and assess long-term outcomes. Additional studies exploring cytokine signatures, integration with checkpoint inhibitors, or combinations with targeted agents may further refine treatment.
Click the link to view the original article：
